What is the epidemiology of HCV?
The prevalence of antibody to HCV (anti-HCV) in the general population of the United States is 1.8%, corresponding to an estimated 3.9 million Americans infected with HCV, and an estimated 8,000 to 10,000 deaths each year result from HCV-associated chronic liver disease.
Is HCV related to HIV?
Infection with both HIV and HCV is called HIV/HCV coinfection. In people with HIV/HCV coinfection, HIV may cause chronic HCV to advance faster.
What HCV 2?
Hepatitis C genotype 2 is often curable. But chronic infection can lead to serious complications. Most people with hepatitis C experience no symptoms or only mild symptoms, even when the liver is becoming damaged. The first six months after infection is defined as acute hepatitis C infection.
How many Hep C genotypes are there?
Scientists call the different types of hepatitis c “genotypes.” Each hepatitis C genotype has a different genetic makeup that helps define it. There are six basic genotypes. Scientists break down each of these numbers into subtypes by letters, like 1a, 1b, etc.
Which HCV is better response for treatment?
Hepatitis C virus (HCV) genotype 2a has a better virologic response to antiviral therapy than HCV genotype 1b – PMC. The . gov means it’s official. Federal government websites often end in .
What is the prevalence of hepatitis C virus (HCV) genotype 2?
In the United States, genotype 2 accounts for approximately 13-15% of all hepatitis C virus (HCV) infections. In the era before direct-acting antiviral agents (DAAs), sustained virologic response rates at 12 weeks post-treatment (SVR12) were relatively higher in persons with genotype 2 HCV than those with genotype 1, 3, or 4 HCV.
What is the initial treatment for HCV genotype 2?
HCV Genotype 2: Initial Treatment. Background. Historically, in the interferon era, treatment of genotype 2 infection achieved higher sustained virologic response (SVR) rates than with genotype 1 infection, even with a shorter duration of therapy and lower doses of ribavirin.
What is the AASLD-IDSA HCV guidance for genotype 2?
Table 1. AASLD-IDSA HCV Guidance for Genotype 2: Initial Treatment Note: *This is taken as 3 tablets once daily with each fixed-dose tablet containing glecaprevir (100 mg)/pibrentasvir (40 mg). Source: AASLD-IDSA.
What factors influence the optimal regimen for retreatment of HCV genotype 2?
For retreatment of adults with HCV genotype 2, four major factors influence the optimal regimen for retreatment, including (1) the prior regimen the patient failed, including whether there was prior exposure to an NS5A inhibitor, (2) the presence or absence of cirrhosis, (3) cost or insurance considerations.